サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1726377

米国の低分子イノベーター原薬CDMO市場：市場規模・シェア・動向分析 (病期別・サービス別・顧客の種類別・治療領域別・地域別)、セグメント別予測 (2025年～2030年)

U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Service, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
米国の低分子イノベーター原薬CDMO市場：市場規模・シェア・動向分析 (病期別・サービス別・顧客の種類別・治療領域別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月25日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の低分子イノベーター原薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の低分子イノベーター原薬CDMOの市場規模は2030年までに126億米ドルに達すると予測され、2025年から2030年までのCAGRは6.0%で成長すると予測されています。

製薬企業のアウトソーシング傾向の高まり、低分子医薬品の需要増加、臨床試験の急増が米国市場にプラスの影響を与えると予測されています。

低分子は世界の新治療開発において重要な役割を果たし続けています。特に新興国市場では、特殊医薬品が米国医薬品の成長をますます牽引するようになっており、特殊医薬品売上の半分以上を低分子医薬品が占めています。さらに、効率性の向上も医薬品アウトソーシングの重要な推進力となっています。新薬の市場導入を急ぐよう製薬会社に求められるプレッシャーが高まる中、アウトソーシングは医薬品開発プロセスを加速させるソリューションとして浮上しています。CDMOは、その専門知識、経験、最先端の設備を活用し、高品質な医薬品の迅速かつ効率的な生産を促進し、製薬企業が開発スケジュールを遵守することを可能にします。

製薬/バイオテクノロジー企業は、その専門知識を活用するためにCDMOサービスを選択することが増えています。CDMOは製造能力の柔軟性と拡張性を提供し、製薬会社が変化する市場の需要に適応し、新治療法の市場投入までの時間を短縮することを可能にします。専門知識の提供やキャッシュフロー管理の改善に加え、アウトソーシングは投資リスクの軽減など製造面でも大きなメリットをもたらします。アーリーステージの技術や製品では、高価な自社製造能力を確立することは、製品開発段階において大きなリスクを伴います。同時に、アウトソーシングはリスク回避の代替案としても機能します。

低分子原薬のアウトソーシングは、製品の市場需要が確立され、理解されるまでの有効な戦略として好まれています。例えば、2022年5月、CDMOであるピラマル・ファーマ・リミテッドのファーマ・ソリューションズ事業は、オンタリオ州オーロラの拠点に新しいAPI施設を開設しました。この最新鋭の工場は操業を開始し、初期生産を完了しました。

米国の低分子イノベーター原薬CDMO市場：分析概要

  • ステージ別では、臨床セグメントが2024年に54.68%の最大売上シェアで市場をリードしえいます。このセグメントの成長は、臨床試験（第I～III相）活動の増加、低分子開発パイプラインの増加、専門知識の利用可能性の増加に起因しています。
  • 顧客の種類別では、医薬品分野が2024年に最大の売上シェアを占め、医薬品開発資金の増加が同分野の成長を後押ししています。
  • 治療分野別では、がん分野が2024年に最大の収益シェアを占めました。さらに、がんの疾病負担を最小化するための先端治療薬への研究開発投資の高さが、同分野の成長を後押しすると期待されています。
  • 2024年の米国市場は、西部が33.07%の最大売上シェアを占めました。慢性疾患の有病率の増加、原薬・CDMOサービスの需要、医療インフラの改善など、さまざまな要因が市場を大きく牽引すると予想されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場動向と展望
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 投資と資金調達の観点
  • 臨床試験の件数分析（2024年）
    • 臨床試験の総数：相別（2024年）
    • 臨床試験の総数：研究デザイン別（2024年）
    • 臨床試験の総数：主要治療領域別（2024年）
  • 技術情勢
    • 低分子イノベーター原薬CDMO市場へのAIの統合
  • 価格モデル分析
  • 規制の枠組み
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL
    • COVID-19の影響分析

第4章 米国の低分子イノベーター原薬CDMO市場：病期別の推定・動向分析

  • セグメントダッシュボード
  • 米国の低分子イノベーター原薬CDMO市場：変動分析、病期別
  • 米国の低分子イノベーター原薬CDMO市場：市場規模と動向分析、病期別（2018～2030年）
  • 前臨床
  • 臨床
    • 第I相
    • 第II相
    • 第III相
  • 上市

第5章 米国の低分子イノベーター原薬CDMO市場：サービス別の推定・動向分析

  • セグメントダッシュボード
  • 米国の低分子イノベーター原薬CDMO市場：変動分析、サービス別
  • 米国の低分子イノベーター原薬CDMO市場：市場規模と動向分析、サービス別（2018～2030年）
  • プロセス開発
    • 前臨床開発
    • 臨床開発
    • スケールアップの最適化
  • 受託製造
    • 臨床
    • 上市
  • 分析試験・品質管理
  • 包装・サプライチェーンソリューション
  • その他

第6章 米国の低分子イノベーター原薬CDMO市場：顧客の種類別の推定・動向分析

  • セグメントダッシュボード
  • 米国の低分子イノベーター原薬CDMO市場：変動分析、顧客の種類別
  • 米国の低分子イノベーター原薬CDMO市場：市場規模と動向分析、顧客の種類別（2018～2030年）
  • 医薬品
    • 小規模企業
    • 中規模企業
    • 大企業
  • バイオテクノロジー
    • 小規模企業
    • 中規模企業
    • 大企業

第7章 米国の低分子イノベーター原薬CDMO市場：治療領域別の推定・動向分析

  • セグメントダッシュボード
  • 米国の低分子イノベーター原薬CDMO市場：変動分析、治療領域別
  • 米国の低分子イノベーター原薬CDMO市場：市場規模と動向分析、治療領域別（2018～2030年）
  • 心血管疾患
  • 腫瘍学
  • 呼吸器疾患
  • 神経学
  • 代謝障害
  • 感染症
  • その他

第8章 米国の低分子イノベーター原薬CDMO市場：地域別のビジネス分析

  • 地域別ダッシュボード
  • 市場規模び予測と動向分析（2018～2030年）
  • 北東
  • 中西部
  • 西部
  • 南部

第9章 競合情勢

  • 企業分類
  • 企業市況分析（2024年）
  • 企業プロファイル
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 4 U.S. small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 5 U.S. small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 6 U.S. small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 U.S. small molecule innovator API CDMO market estimates and forecasts, by region, 2018 - 2030 (USD Million)
  • Table 8 Northeast small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 9 Northeast small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 10 Northeast small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 11 Northeast small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 12 Northeast small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 New Jersey small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 14 New Jersey small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 15 New Jersey small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 16 New Jersey small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 17 New York small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 18 New York small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 19 New York small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 20 New York small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 22 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 23 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 24 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 25 Midwest small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 26 Midwest small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 27 Midwest small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 28 Midwest small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 29 Midwest small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 30 Missouri small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 31 Missouri small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Missouri small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 33 Missouri small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 34 North Carolina small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 35 North Carolina small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 36 North Carolina small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 37 North Carolina small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 38 West Group small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 39 West Group small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 40 West Group small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 41 West Group small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 42 West Group small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 43 California small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 44 California small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 45 California small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 46 California small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 47 Washington small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 48 Washington small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 49 Washington small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 50 Washington small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 52 South small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 53 South small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 54 South small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 55 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 56 Texas small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 57 Texas small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 58 Texas small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 59 Texas small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60 Florida small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 61 Florida small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 62 Florida small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 63 Florida small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 64 Georgia small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 65 Georgia small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 66 Georgia small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 67 Georgia small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 small molecule innovator API CDMO market, Segmentation
  • Fig. 7 Market driver analysis
  • Fig. 8 Market restraint relevance analysis
  • Fig. 9 Porter's five forces analysis
  • Fig. 10 PESTEL by SWOT analysis
  • Fig. 11 Regional marketplace: Key takeaways
  • Fig. 12 U.S. preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. process development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. preclinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. clinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. scale-up optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. analytical testing and quality control market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. packaging and supply chain solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. small pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. medium pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. large pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. small biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. medium biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. large biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. metabolic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Regional Outlook, 2024 & 2030
  • Fig. 44 Northeast small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Massachusetts small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Midwest small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 North Carolina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 West Group small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Georgia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-297-9

U.S. Small Molecule Innovator API CDMO Market Growth & Trends:

The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights:

  • Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
  • Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
  • Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
  • West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Information Analysis
    • 1.4.2. Market Formulation & Data Visualization
    • 1.4.3. Data Validation & Publishing
  • 1.5. Model Details
    • 1.5.1. Commodity Flow Analysis (Model 1)
    • 1.5.2. Top Down Market Estimation (Model 2)
    • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
    • 1.5.4. Multivariate Analysis (Model 4)
  • 1.6. List of Secondary Sources
  • 1.7. List of Abbreviations
  • 1.8. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Investments & Funding Perspective
  • 3.5. Clinical Trials Volume Analysis, (2024)
    • 3.5.1. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.2. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Technology Landscape
    • 3.6.1. Integration Of AI In Small Molecule Innovator API CDMO Market
  • 3.7. Pricing Model Analysis
  • 3.8. Regulatory Framework
  • 3.9. Industry Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis
    • 3.9.3. COVID-19 Impact Analysis

Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Small Molecule Innovator API CDMO Market; Stage Type Movement Analysis
  • 4.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
  • 4.4. Preclinical
    • 4.4.1. Preclinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Clinical
    • 4.5.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Phase I
      • 4.5.2.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Phase II
      • 4.5.3.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Phase III
      • 4.5.4.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Commercial
    • 4.6.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Small Molecule Innovator API CDMO Market; Service Movement Analysis
  • 5.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Preclinical development
      • 5.4.2.1. Preclinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Clinical development
      • 5.4.3.1. Clinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Scale-up optimization
      • 5.4.4.1. Scale-up optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Clinical
      • 5.5.2.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Commercial
      • 5.5.3.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Analytical Testing and Quality Control
    • 5.6.1. Analytical testing and quality control market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Packaging and Supply Chain Solutions
    • 5.7.1. Packaging and supply chain solutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Small Molecule Innovator API CDMO Market; Customer Type Movement Analysis
  • 6.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical
    • 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Small
      • 6.4.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Medium
      • 6.4.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Large
      • 6.4.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Biotechnology
    • 6.5.1. Biotechnology market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Small
      • 6.5.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Medium
      • 6.5.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Large
      • 6.5.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Small Molecule Innovator API CDMO Market; Therapeutic Area Movement Analysis
  • 7.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Cardiovascular Diseases
    • 7.4.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Respiratory Disorders
    • 7.6.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Neurology
    • 7.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Metabolic Disorders
    • 7.8.1. Metabolic disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Infectious Diseases
    • 7.9.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
  • 8.3. Northeast
    • 8.3.1. Competitive scenario
    • 8.3.2. Northeast small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. New Jersey
      • 8.3.3.1. Competitive scenario
      • 8.3.3.2. New Jersey small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. New York
      • 8.3.4.1. Competitive scenario
      • 8.3.4.2. New York small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Massachusetts
      • 8.3.5.1. Competitive scenario
      • 8.3.5.2. Massachusetts small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4. Midwest
    • 8.4.1. Competitive scenario
    • 8.4.2. Midwest small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Illinois
      • 8.4.3.1. Competitive scenario
      • 8.4.3.2. Illinois small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Missouri
      • 8.4.4.1. Competitive scenario
      • 8.4.4.2. Missouri small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. North Carolina
      • 8.4.5.1. Competitive scenario
      • 8.4.5.2. North Carolina small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. West Group
    • 8.5.1. Competitive scenario
    • 8.5.2. West Group small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. California
      • 8.5.3.1. Competitive scenario
      • 8.5.3.2. California small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. Washington
      • 8.5.4.1. Competitive scenario
      • 8.5.4.2. Washington small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. South
    • 8.6.1. Competitive scenario
    • 8.6.2. South small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Texas
      • 8.6.3.1. Competitive scenario
      • 8.6.3.2. Texas small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Florida
      • 8.6.4.1. Competitive scenario
      • 8.6.4.2. Florida small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Georgia
      • 8.6.5.1. Competitive scenario
      • 8.6.5.2. Georgia small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Lonza Group Ltd.
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Novo Holdings (Catalent, Inc.)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Thermo Fisher Scientific, Inc.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Siegfried Holding AG
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Recipharm AB
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. CordenPharma International
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Samsung Biologics
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Labcorp
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Ajinomoto Bio-Pharma Services
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Piramal Pharma Solutions
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Service benchmarking
      • 9.3.11.4. Strategic initiatives